Optimisation of the use of tranexamic acid, a medication used to treat or prevent excessive blood loss during total knee replacement surgery

Not Applicable

Completed

• Conditions: osteoarthritis; total knee arthroplasty; Musculoskeletal - Osteoarthritis; Surgery - Other surgery

• Registration Number: ACTRN12619000339156
• Lead Sponsor: Wesley Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-05
• Study Completion: 2019-11-20
• Last Update Posted: 6 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

participants of either sex scheduled to undergo a primary, unilateral TKA (either anterior or posterior approach, but not joint resurfacing)
- available for follow up at 6 months post-surgery
- willingness to provide written, informed consent
- willingness to comply with the study

Exclusion Criteria

- known allergy to TXA
- acquired disturbances to colour vision
- preoperative use of anticoagulants (within 5 days of surgery)
- fibrinolytic disorders requiring intraoperative fibrinolytics
- coagulopathy, history of arteriolar or venous thromboembolic disease
- pregnancy or breastfeeding
- hepatic failure
- haemoglobin <10g/dL

Study & Design

• Study Type: Interventional
• Study Design: Not specified